178 related articles for article (PubMed ID: 22563191)
21. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response.
Cheetham S; Tang MJ; Mesak F; Kennecke H; Owen D; Tai IT
Br J Cancer; 2008 Jun; 98(11):1810-9. PubMed ID: 18458674
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor effect of 5-aza-2'-deoxycytidine by inhibiting telomerase activity in hepatocellular carcinoma cells.
Tao SF; Zhang CS; Guo XL; Xu Y; Zhang SS; Song JR; Li R; Wu MC; Wei LX
World J Gastroenterol; 2012 May; 18(19):2334-43. PubMed ID: 22654424
[TBL] [Abstract][Full Text] [Related]
23. Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma.
He Y; Cui Y; Wang W; Gu J; Guo S; Ma K; Luo X
Neoplasia; 2011 Sep; 13(9):841-53. PubMed ID: 21969817
[TBL] [Abstract][Full Text] [Related]
24. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers.
Yang E; Kang HJ; Koh KH; Rhee H; Kim NK; Kim H
Int J Cancer; 2007 Aug; 121(3):567-75. PubMed ID: 17397030
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of expression and promoter hypermethylation of XAF1 in hepatitis B virus-associated hepatocellular carcinoma treated with transplantation.
Zhang F; Wu LM; Zhou L; Chen QX; Xie HY; Feng XW; Zheng SS
Ann Surg Oncol; 2008 Dec; 15(12):3494-502. PubMed ID: 18830757
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells.
Atorrasagasti C; Malvicini M; Aquino JB; Alaniz L; Garcia M; Bolontrade M; Rizzo M; Podhajcer OL; Mazzolini G
Int J Cancer; 2010 Jun; 126(11):2726-40. PubMed ID: 19830689
[TBL] [Abstract][Full Text] [Related]
27. Aberrant methylation of TRIM58 in hepatocellular carcinoma and its potential clinical implication.
Qiu X; Huang Y; Zhou Y; Zheng F
Oncol Rep; 2016 Aug; 36(2):811-8. PubMed ID: 27373520
[TBL] [Abstract][Full Text] [Related]
28. Identification of the A kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma.
Hayashi M; Nomoto S; Kanda M; Okamura Y; Nishikawa Y; Yamada S; Fujii T; Sugimoto H; Takeda S; Kodera Y
J Surg Oncol; 2012 Mar; 105(4):381-6. PubMed ID: 22052684
[TBL] [Abstract][Full Text] [Related]
29.
Anwar SL; Krech T; Hasemeier B; Schipper E; Schweitzer N; Vogel A; Kreipe H; Buurman R; Skawran B; Lehmann U
World J Gastroenterol; 2017 Mar; 23(9):1568-1575. PubMed ID: 28321157
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma.
Xie B; Zhou J; Yuan L; Ren F; Liu DC; Li Q; Shu G
Hum Pathol; 2013 May; 44(5):795-801. PubMed ID: 23123137
[TBL] [Abstract][Full Text] [Related]
31. The interferon-alpha responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma.
Zhou X; Popescu NC; Klein G; Imreh S
Cancer Genet Cytogenet; 2007 Aug; 177(1):6-15. PubMed ID: 17693185
[TBL] [Abstract][Full Text] [Related]
32. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].
Lou C; Yang B; Gao YT; Wang YJ; Nie FH; Yuan Q; Zhang CL; Du Z
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):831-6. PubMed ID: 19173828
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic and prognostic values of apolipoprotein D alterations in hepatocellular carcinoma.
Utsunomiya T; Ogawa K; Yoshinaga K; Ohta M; Yamashita K; Mimori K; Inoue H; Ezaki T; Yoshikawa Y; Mori M
Int J Cancer; 2005 Aug; 116(1):105-9. PubMed ID: 15756681
[TBL] [Abstract][Full Text] [Related]
34. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma.
Wong CM; Ng YL; Lee JM; Wong CC; Cheung OF; Chan CY; Tung EK; Ching YP; Ng IO
Hepatology; 2007 May; 45(5):1129-38. PubMed ID: 17464989
[TBL] [Abstract][Full Text] [Related]
35. Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma.
Lu B; Ma Y; Wu G; Tong X; Guo H; Liang A; Cong W; Liu C; Wang H; Wu M; Zhao J; Guo Y
Clin Cancer Res; 2008 Nov; 14(22):7405-12. PubMed ID: 19010857
[TBL] [Abstract][Full Text] [Related]
36. Aberrant methylation of SPARC in human lung cancers.
Suzuki M; Hao C; Takahashi T; Shigematsu H; Shivapurkar N; Sathyanarayana UG; Iizasa T; Fujisawa T; Hiroshima K; Gazdar AF
Br J Cancer; 2005 Mar; 92(5):942-8. PubMed ID: 15756262
[TBL] [Abstract][Full Text] [Related]
37. Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
Liu T; Qiu X; Zhao X; Yang R; Lian H; Qu F; Li X; Guo H
Oncol Rep; 2018 Feb; 39(2):659-666. PubMed ID: 29207175
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of aberrant cyclin-dependent kinase-like 2 methylation in hepatocellular carcinoma.
Zhou Y; Qiu XP; Li ZH; Zhang S; Rong Y; Yang GH; Fang-Zheng
Gene; 2019 Jan; 683():35-40. PubMed ID: 30292871
[TBL] [Abstract][Full Text] [Related]
39. DNA methylation profiling identifies EYA4 gene as a prognostic molecular marker in hepatocellular carcinoma.
Hou X; Peng JX; Hao XY; Cai JP; Liang LJ; Zhai JM; Zhang KS; Lai JM; Yin XY
Ann Surg Oncol; 2014 Nov; 21(12):3891-9. PubMed ID: 24306662
[TBL] [Abstract][Full Text] [Related]
40. DNA binding protein A expression and methylation status in hepatocellular carcinoma and the adjacent tissue.
Yasen M; Obulhasim G; Kajino K; Mogushi K; Mizushima H; Tanaka S; Tanaka H; Hino O; Arii S
Int J Oncol; 2012 Mar; 40(3):789-97. PubMed ID: 22159460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
